ProfileGDS5678 / 1445061_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 36% 36% 34% 35% 40% 38% 36% 35% 36% 36% 34% 47% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8605936
GSM967853U87-EV human glioblastoma xenograft - Control 22.8147836
GSM967854U87-EV human glioblastoma xenograft - Control 32.8181136
GSM967855U87-EV human glioblastoma xenograft - Control 42.7269134
GSM967856U87-EV human glioblastoma xenograft - Control 52.7597635
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0034540
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9369638
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8046836
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7644235
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7955336
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8021536
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7445134
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1184147
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8048836